New York, NY – November 16, 2018 Kali, Inc. (USOTC: KALY) is recommended as a “BUY” today by AmericBulls.com following yesterday’s announcement that KALY had finalized the acquisition of NCM Biotech, the developer and owner of a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” The KALY news reported the company plans to leverage the patent to enter the cannabis pharmaceuticals and concentrates market. The news yesterday further reported that the cannabis pharmaceuticals market is forecasted to reach $50 billion in sales by 2029, and that the cannabis concentrates for wellness, edibles and recreational markets is forecasted to reach $8.5 billion in annual sales by 2022.
“Our system’s recommendation today is to BUY. The BULLISH HARAMI pattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.0038, and our valid average buying price stands now at 0.0039 …
The green light is on and this security is now screaming BUY. It is action time! The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. Do not miss this bullish opportunity.”
KALY’s news yesterday included more information on the company’s plans to expand with a differentiated service in the cannabis pharmaceuticals and concentrates sector. “Kali, with its recent acquisition of NCM Biotech, has separately announced entering into a joint venture (JV) company called US Cannabis Health with Puration [PURA] and Nouveau life Pharmaceuticals (USOTC: NOUV).”
Notably, the news yesterday emphasized that KALY had no plans for a reverse split in conjunction with the patented cannabis extraction acquisition.
In reference to what all comes with the acquisition, KALY’s news yesterday included the following:
“NCM Biotech’s current research and ongoing pharmaceutical developments come with the acquisition. Commenting on the research NCM Biotech has undertaken with notable medical institutions in the North East, Frederick Ferri, CEO and Founder of NCM Biotech said, “Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical [GWPH] products and candidate products. “ “
DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.